GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial will enroll up to 42 patients in Finland across four cohorts
One task, one interaction, one pair, experts advocate
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
Nearly 12 million people are estimated to be living with glaucoma, making the country one of the worst affected globally
Launches advanced bone density systems in India & Dubai
Subscribe To Our Newsletter & Stay Updated